West Pharmaceutical Services’ Q2 2025 Earnings: What to Expect

$ 16 billion by the market, West Pharmaceutical Services, Inc. (WST) is the leading global company in the field of packaging and delivery of the drugs that have been injected. Its headquarters is located in Exton, Pennsylvania, the company offers pharmaceutical clients and vital technology all over the world with products such as rubber plugs, seals, and car injection.

The company is ready to announce its profits in the second quarter of 2025 before the opening of the market on Thursday, July 24. Before the event, analysts expect WST a profit of $ 1.51 per share on a reduced basis, with a marginal decrease of $ 1.52 per share per year. The company won the unanimity estimates in three of the last four quarters, while losing expectations on another occasion.

For the current year, analysts expect to reach the share profitability of $ 6.28, a decrease of 7 % from $ 6.75 in the fiscal year 2024. However, the share profitability is expected to rise 14.2 % on an annual basis to $ 7.17 in the fiscal year 2026.

WST shares have left well behind the broader market standards over the past 52 weeks, as they decreased by 30.7 %, on the blatant contrast with S&P 500 ($ SpX) gains 13.4 %. The stock was also worse than the SPDR SPDR in health care (XLV), which was rejected by 5.4 % more modest during the same period.

On April 24, WST shares decreased by 3.5 % after the company reported the results of the first quarter. While revenues amounted to up to $ 698 million, which reflects organic growth by 2.1 %, the profitability of the modified stock of $ 1.45 is the expectations of analysts of $ 1.23. Despite the decrease in shares, the administration raised its expectations for the entire year, as it offered revenues between $ 2.945 and 2.975 billion dollars and Lord of the profitability of the modified stock in the range of $ 6.15 to $ 6.35, which represents an expected impact between 20 and 25 million dollars of customs tariffs.

The opinion of analysts in the consensus of WST stocks is very optimistic, with a “strong purchase” classification in general. Of the 13 analysts covering the arrow, 10 is advised to classify “strong purchase”, one that gives “moderate purchase”, and two suggest “Hold”.

The average price of the WST analyst is $ 279.55, indicating the presence of ambitious capabilities of up to 25.8 % of the current levels.

On the date of publication, Kritika Sarmah did not have positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are only for media purposes. This article was originally published on Barchart.com